Harbour BioMed Announces Dosing of First Patient in Combination Therapy Phase Ib/IIa Trial of Next-Generation Anti-CTLA-4 Antibody
Post Views: 939 CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ — Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successfully completed the dosing of first patient in phase Ib/IIa trial at the stage of dose expansion of its anti-CTLA-4 antibody (HBM4003) in combination therapy with toripalimab (anti-PD-1 antibody) for…